Skip to main content

Table 3 Top significantly enriched canonical pathways of LncRNAs in PVR patients

From: Coding and non-coding RNA interactions reveal immune-related pathways in peripheral blood mononuclear cells derived from patients with proliferative vitreoretinopathy

Ingenuity canonical pathways

−log(p value)

Ratio

Molecules

D-myo-inositol-5-phosphate metabolism

2.85

0.0641

DOT1L, INPP5B, MDP1, NUDT5, PLCG1, PPIP5K1, PPP2R5A, PTPN6, PTPRM, SET

Superpathway of inositol phosphate compounds

2.12

0.0505

DOT1L, INPP5B, MDP1, NUDT5, PLCG1, PPIP5K1, PPP2R5A, PTPN6, PTPRM, SET

Endocannabinoid cancer inhibition pathway

2.04

0.0559

ATF3, CREB1, GNB1L, LEF1, MAP2K4, PRKACA, SPTLC1, TCF4

Heme biosynthesis II

1.87

0.222

HMBS, UROD

Folate transformations I

1.87

0.222

MTHFD2, MTHFR

Salvage pathways of pyrimidine ribonucleotides

1.84

0.0619

CSNK1D, GRK4, MAP2K4, MAPK6, PRKCH, UCKL1

Protein kinase a signaling

1.76

0.0377

ADD1, ADD3, APEX1, CHP1, CREB1, FLNA, GNB1L, LEF1, PLCG1, PRKACA, PRKCH, PTPN4, PTPN6, PTPRM, TCF4

Amyloid processing

1.73

0.08

CAPN2, CSNK1D, PRKACA, PSEN2

Androgen signaling

1.66

0.0515

GNA12, GNB1L, KAT7, NCOA1, POLR2J2/POLR2J3, PRKACA, PRKCH

Virus entry via endocytic pathways

1.65

0.0561

AP2A1, FLNA, ITGAL, ITGB1, PLCG1, PRKCH